Home ›
Prostate Cancer Trials ›
NCT07216248
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Trial Details
NCT ID NCT07216248 Phase PHASE2
Sponsor University of Utah
Status RECRUITING
Cancer Type Prostate Cancer
Interventions relugolix + ARPI Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI relugolix or androgen deprivation therapy (ADT) + ARPI relugolix + ARPI. Locations (sample) Salt Lake City, Utah, United States|40.76078,-111.89105
Key Eligibility Criteria
Cohort A Eligibility (Step 1 Registration) Participant aged ≥ 18 years Hormone-sensitive prostate cancer with histologically/cytologically confirmed adenocarcinoma without small cell histology. Metastasis detected any time prior to study registration on conventional or functional imaging as determined by the treating investigator and can b… For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →